Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Bristol-Myers Squibb
Age
18–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Body mass index (BMI) of 18 to 32 kg/m2, inclusive BMI = weight (kg)/\[height(m)\]2
You may not be if
WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of investigational product
Abnormal liver functions tests (ALT, AST or total bilirubin \> 10% above ULN)
History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months
History of allergy to SGLT@ inhibitors, DPP$ inhibitors or sulfonylurea or related compounds
Prior exposure to dapagliflozin, sitagliptin and glimepiride within 3 months of Day -1
History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections
Clareo Health | Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
